Geron Corporation, a clinical-stage biopharmaceutical company headquartered in Menlo Park, United States, operates within the health care sector, specifically focusing on biotechnology. The company is renowned for its development of telomerase inhibitors, with imetelstat being a notable product aimed at treating hematologic myeloid malignancies. Geron serves its clientele primarily in California and is publicly traded on the Nasdaq stock exchange.
As of November 17, 2025, Geron’s stock closed at $1.11. The company’s financial performance over the past year has seen significant fluctuations, with a 52-week high of $4.21 recorded on November 26, 2024, and a 52-week low of $1.04 on November 6, 2025. These figures reflect the volatility in the biotechnology sector and the challenges faced by companies in the clinical development phase.
Geron’s market capitalization stands at approximately $695.8 million USD, indicating its valuation in the market. However, the company’s price-to-earnings (P/E) ratio is currently at -9.16, suggesting that it is not generating positive earnings at this time. This negative P/E ratio is not uncommon for companies in the biotechnology industry, particularly those in the clinical stages of drug development, as they often incur significant research and development expenses.
Founded in 1996, Geron made its initial public offering (IPO) on June 30 of the same year. Since then, the company has focused on advancing its pipeline of innovative therapies, with imetelstat being a key focus due to its potential in treating various cancers by targeting telomerase, an enzyme that plays a crucial role in cellular aging and cancer cell proliferation.
For those interested in learning more about Geron’s research initiatives and product offerings, further information is available on their official website at www.geron.com . The company continues to pursue its mission of developing groundbreaking therapies to address unmet medical needs, particularly in the realm of oncology.
